Arbutus to report third quarter 2024 financial results and provide corporate update

Warminster, pa., oct. 23, 2024 (globe newswire) -- arbutus biopharma corporation (nasdaq: abus), (“arbutus” or the “company”) a clinical-stage biopharmaceutical company leveraging its extensive virology expertise to develop a functional cure for people with chronic hepatitis b virus (chbv) infection, today announced that it has scheduled its third quarter 2024 financial results and corporate update for wednesday, november 6, 2024. the schedule for the press release and conference call/webcast are as follows:
ABUS Ratings Summary
ABUS Quant Ranking